Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC).

被引：0
|
作者：
Snedecor, S. J.
Carter, J. A.
Kaura, S.
Botteman, M.
机构：
[1] Pharmerit North Amer, Bethesda, MD USA
[2] Nova Pharmaceut Corp, Oncol Hlth Econ & Outcomes Res, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4581
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Number Needed to Treat (NNT) as a Measure of Incremental Drug Benefit: Denosumab Vs. Zoledronic Acid for the Prevention of Skeletal Related Events (SREs) in Castration-Resistant Prostate Cancer (CRPC)
    Dranitsaris, G.
    Kaura, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S259 - S259
  • [22] Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis.
    Zhong, Lixian
    Srinivas, Sandy
    Pon, Vickie
    Nicole Nguyen
    Frear, Meghan
    Kwan, Sherry
    Gong, Cynthia
    Malmstrom, Robert
    Loucks, Aimee
    Wilson, Leslie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate
    Miyashita, Hirotaka
    Cruz, Christina
    Patel, Vaibhav
    SUPPORTIVE CARE IN CANCER, 2022, 30 (02) : 981 - 984
  • [24] Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate
    Hirotaka Miyashita
    Christina Cruz
    Vaibhav Patel
    Supportive Care in Cancer, 2022, 30 : 981 - 984
  • [25] COMPARING THE EFFICACY OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR PREVENTION OF SKELETAL-RELATED EVENTS (SRES): A CRITICAL APRAISAL OF THREE PIVOTAL TRIALS
    Strite, S.
    Stuart, M. E.
    Beckman, V
    Oehrling, K.
    VALUE IN HEALTH, 2015, 18 (03) : A192 - A193
  • [26] Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
    Howard, L. E.
    De Hoedt, A. M.
    Aronson, W. J.
    Kane, C. J.
    Amling, C. L.
    Cooperberg, M. R.
    Terris, M. K.
    Divers, C. H.
    Valderrama, A.
    Freedland, S. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (04) : 380 - 384
  • [27] Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.
    Lipton, Allan
    Fizazi, Karim
    Stopeck, Alison
    Henry, David H.
    Smith, Matthew Raymond
    Shore, Neal D.
    Martin, Miguel
    Vadhan-Raj, Saroj
    Zhou, Kefei
    Balakumaran, Arun
    Braun, Ada H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Incidence of skeletal-related events in men with castration-resistant prostate cancer.
    Kawai, Alison Tse
    Martinez, David
    Saltus, Catherine W.
    Vassilev, Zdravko
    Soriano-Gabarro, Montse
    Kaye, James A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (34)
  • [29] Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India
    Wadhwa, Raina
    Gupta, Nidhi
    Dixit, Jyoti
    Malhotra, Pankaj
    Lakshmi, P. V. M.
    Prinja, Shankar
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [30] Real world skeletal related events (SREs) associated with oral treatments in patients with metastatic castration resistant prostate cancer (mCRPC).
    Engel-Nitz, Nicole
    Behl, Ajay S.
    Blauer-Peterson, Cori
    Dawson, Nancy Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345